December 13, 2011

Genentech initiates First-in-Human study with NovImmune’s anti-IL17 antibody

NovImmune announced today that Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), initiated a First-in-Human study with anti-IL-17 (NI-1401, RG7624), a fully human monoclonal antibody designed to specifically and selectively bind to the human IL-17 family of cytokines.

PDF Download

read more »

November 15, 2011

EU approves use of Stevia in food and beverages

Evolva Holding SA (SIX: EVE) today announced that the European Commission has approved the use of steviol glycosides in food and beverages in the European Union. After the earlier clearance by regulators in the US and many other regions of the world, this marks a major breakthrough in the acceptance of Stevia as a natural, zero-calorie sweetener.

PDF download English version
PDF download German version

read more »

November 07, 2011

Evolva receives clearance to move EV-077 into Phase IIa

Evolva Holding SA (SIX: EVE) announced today that it has received regulatory clearance to progress its pharmaceutical compound EV-077 into Phase IIa clinical studies for the treatment of complicatio ns of diabetes.

PDF Download English Version
PDF Download German Version

read more »

October 25, 2011

S*BIO to Initiate Global Phase 3 Clinical Trials of its Novel JAK2 Inhibitor Pacritinib for Treatment of Myelofibrosis (MF)

S*BIO Pte Ltd today announced plans to initiate a global Phase 3 clinical program of its novel JAK2 inhibitor pacritinib (SB1518), in the first half of 2012 to further demonstrate its activity and tolerability for the treatment of myelofibrosis (MF). The company is actively exploring partnering opportunities for the advancement of its leading JAK2 program.

PDF Download

read more »

October 02, 2011

Symetis’ ACURATE TA™ Aortic Bioprosthesis Receives CE

Symetis SA, a private Swiss company developing new transcatheter aortic valve implantation (TAVI) systems, announced during the Techno-College at the EACTS (European Association for Cardio-Thoracic Surgery) meeting in Lisbon that it received CE Mark approval for its ACURATE TA™ transapical TAVI system. The approval of this 2nd generation TAVI device, used to treat elderly patients with severe aortic stenosis (AS) for whom open surgical repair is considered to be high risk, opens the company to a market estimated to exceed $2 billion by 2014.
PDF Download

read more »

September 27, 2011

Biotie to Acquire Newron Creating a Leading European Biopharmaceutical Company Focused on Central Nervous System Drug Development

Biotie Therapies Corp. ("Biotie" or "Company", NASDAQ-OMX; BTH1V) and Newron Pharmaceuticals S.p.A. ("Newron", SIX; NWRN) today announced that they have signed an agreement for Biotie to acquire Newron in a transaction valued at EUR 45 million (the "Transaction").

PDF Download
PDF Download Appendix

read more »

September 22, 2011

Bristol-Myers Squibb and Ambrx Announce Collaboration for Novel Biologics Programs in Diabetes and Heart Failure

Bristol-Myers Squibb Company (NYSE: BMY) and Ambrx, Inc. today announced a collaboration under which Bristol-Myers Squibb will receive exclusive worldwide rights to research, develop and commercialize biologics based on Ambrx’s research surrounding the Fibroblast Growth Factor 21 (FGF-21) protein, for potential use in treating type 2 diabetes, and the Relaxin hormone, for potential use in treating heart failure.
PDF Download

read more »

July 25, 2011

Positive ex vivo data on EV-077 in diabetics presented at ISTH conference in Kyoto, Japan

Evolva Holding SA (SIX: EVE), which is developing novel medicines and nutritional ingredients through synthetic biology, announced that data on its lead drug candidate EV-077 were presented in an oral presentation today at the XXIII Congress of the International Society on Thrombosis and Haemostasis (ISTH), taking place in Kyoto, Japan.
PDF Download English Version
PDF Download German Version

read more »

July 08, 2011

Evolva completes Abunda acquisition

Evolva Holding SA (SIX: EVE), which is developing novel medicines and nutritional ingredients through synthetic biology, announced that it will complete the acquisition of Abunda Nutrition, Inc. (“Abunda”) today, after which it will be a wholly-owned subsidiary of Evolva.
PDF download English version
PDF download German version

read more »

June 15, 2011

Biotie Announces Completion of Phase 3 Program with Nalmefene in Alcohol

Biotie's partner, H. Lundbeck A/S (Lundbeck), has today announced the completion of ESENSE2, the last study in its Phase 3 program evaluating nalmefene for the treatment of alcohol dependence. Results from this 718 patient, double-blind, placebo controlled trial were consistent with the profile observed in
previous clinical studies of nalmefene. Lundbeck plans to file a marketing authorization application (MAA) in Europe by the end of 2011.
PDF Download

read more »

June 14, 2011

Evolva to receive first milestone payment from Roche

Evolva Holding SA (SIX: EVE) today announced that Roche (SIX: ROG, RO; OTCQX: RHHBY) has confirmed that Evolva has achieved its first milestone in their collaboration. Roche will now make a corresponding milestone payment (of an undisclosed amount) to Evolva. The milestone relates to the achievement of diverse,
purified active compounds that derive from Evolva’s synthetic biology platform. The milestone payment does not change Evolva’s cash flow guidance for 2011.
PDF Download English Version
PDF Download German Version

read more »

June 01, 2011

Additional Data from Multiple Phase 1 and 2 Studies of S*BIO’s Novel JAK2

S*BIO Pte Ltd today announced that additional data from multiple Phase 1 and 2 clinical studies of its novel JAK2 inhibitor SB1518 further confirmed safety and efficacy for the treatment of patients with symptomatic myelofibrosis (MF) and enlarged spleens. In the studies, SB1518 alleviated MF-associated splenomegaly and showed no evidence of myelosuppression and no exacerbation of cytopenias. Results will be presented at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago and the 16th Congress of the European Hematology Association (EHA) in London.
PDF Download

read more »

May 14, 2011

Symetis reports on its trans-apical ACURATE TA™ clinical

Symetis SA, a private Swiss company developing new transcatheter aortic valve implantation (TAVI) systems, announced today during the Late-Breaking Trials session at EuroPCR 2011 (Paris – France), the 6 month results of its ACURATE TA™ first-in-man (FIM) clinical study. In addition, Symetis reported having enrolled 75 patients between its FIM and Pilot studies, sufficient to support the filing of its ACURATE TA™ CE mark application.
PDF Download

read more »

May 02, 2011

Evolva appoints Norbert Bender as Chief Medical Officer

Evolva Holding SA (SIX: EVE) announces today that it has appointed Norbert Bender, M.D, Ph.D., an experienced drug development professional, as its Chief Medical Officer (CMO) with immediate effect.
PDF Download English Version
PDF Download German Version

read more »

April 26, 2011

Evolva proposes two leading biotech and food ingredient executives to join its Board

Evolva Holding SA (SIX: EVE) has today published the agenda items for the Annual General Meeting, to be held on 18 May 2011 in Basel. Registered shareholders will receive the full agenda including the Board’s proposals by post. The invitation is also available on our website (www.evolva.com).
PDF Download English Version
PDF Download German Version

read more »

April 14, 2011

S*BIO Initiates Phase 2 Clinical Trial of its Novel JAK2 Inhibitor SB1518 in North America for

S*BIO Pte Ltd today announced that it has dosed the first 10 patients in a Phase 2 clinical trial of its novel JAK2 inhibitor SB1518 in the U.S. and Canada for the treatment of advanced lymphoid malignancies.
PDF Download

read more »

April 05, 2011

Evolva to Acquire Abunda Nutrition

Evolva Holding SA (SIX: EVE) announces today that it plans to acquire its R&D partner Abunda Nutrition, Inc. Evolva and San Francisco-based Abunda have collaborated on the development of Abunda’s next-generation nutritional ingredients since 2009. One part of this collaboration, using Evolva’s proprietary technology, succeeded in making the key components of the natural high intensity sweetener Stevia via fermentation in yeast.
PDF Download English Version
PDF Download German Version

read more »

March 31, 2011

Omeros Reports Outcome of Phase 3 Trials of OMS103HP

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today reported the outcome from its Phase 3 program evaluating OMS103HP in patients undergoing  arthroscopic anterior cruciate ligament (ACL) reconstruction surgery. OMS103HP did not meet the pre-specified endpoints of these studies.
PDF Download

read more »

March 28, 2011

FDA clears Evolva’s IND for EV-077 in influenza

Evolva Holding SA (SIX: EVE) today announced that the US Food and Drug Administration (FDA) has cleared Evolva’s request to test EV-077 in man, under an Investigational New Drug (IND) application for influenza.
PDF Download English Version
PDF Download German Version

read more »

March 15, 2011

Omeros Deutsche Bank Research March 2011

Omeros reported a Q4 loss per share of ($0.34) vs our est of ($0.71). The primary reason for the narrower loss was later-than-expected timing of the commercial infrastructure build-out to prepare for the launch of OMS103HP. Excluding this item ($8M), our net loss per share est would have been ($0.35). The co ended Q4 with $42M in cash and short-term investments (up from $35M at the end of Q3). Taking into account the recent Vulcan and Patabios transactions, we estimate that  operating cash burn in the quarter was approx $5M.
PDF Download

read more »

March 11, 2011

Biotie raises EUR 27 million from institutional and strategic investors

Biotie Therapies Corp. ("Biotie") is pleased to announce that it has executed a private placement of shares (the "Offering") in the amount of EUR 27 million that has been fully subscribed for. The shares have been allocated to Finnish and international institutional and strategic investors. A total of 35,230,000 newly issued and
14,747,084 treasury shares were offered in the Offering at a subscription price of EUR 0.54 per share. Subsequent to the completion of the Offering, Biotie's cash, cash equivalents and short term investments will amount to over EUR 45 million.
PDF Download

read more »

March 07, 2011

BASF and Evolva enter into a collaboration to develop compounds applied to protect crops

BASF SE, Ludwigshafen (Germany) and Evolva Holding SA, Reinach (Switzerland) today announced that they have signed an agreement for joint research on the design of novel and optimised biosynthesis routes for selected natural products with crop protection potential.
PDF Download English Version
PDF Download German Version

read more »

January 13, 2011

Evolva enters into collaboration with International Flavours & Fragrances Inc

Evolva Holding SA (SIX: EVE) today announced that it has entered into a collaboration and joint development agreement with International Flavors & Fragrances Inc. (IFF), one of the world’s leading creators and manufacturers of flavors and fragrances for consumer products. The objective of the collaboration is to implement a commercially viable biosynthetic route for the production of a key flavoring ingredient.
PDF Download English Version
PDF Download German Version

read more »

January 11, 2011

Biotie and Synosia to Combine to Create a Leading CNS Development Company

Biotie Therapies Corp. ("Biotie" or "Company", NASDAQ-OMX; BTH1V) and Synosia Therapeutics Holding AG ("Synosia") jointly announce today the signing of a combination agreement through which Biotie will issue 161,448,371 shares to the shareholders and warrant holders of privately-owned Synosia in an acquisition of the entire issued share capital and outstanding warrants of Synosia (the "Transaction").
PDF Download

read more »

January 11, 2011

MerLion Signs License Agreement with Alcon to Develop and Commercialize Novel Finafloxacin Otic Product

MerLion Pharmaceuticals Pte Ltd today announced the signing of an agreement with Alcon Pharmaceuticals, Ltd. an affiliate of Alcon, Inc., by which Alcon obtains exclusive rights from MerLion for the development and commercialization in North America of finafloxacin specifically for treating ear infections.
PDF Download

read more »